ClinicalTrials.gg
CompletedNCT03682302PLAYUpdated Jan 6, 2021Results posted

Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

A Phase 3 interventional study of Exparel and 0.5% Bupivacaine HCl in Postoperative Pain Management, sponsored by Pacira Pharmaceuticals, Inc. Completed at 17 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-01-06.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.

Enrollment
38th of 93
98 · median 80
Started
2019
with 14 others
Phase 3
11 of 93
none open now
Registered
39th of 93
by date
Lead sponsor
11 of 93
Pacira Pharmaceuticals, Inc

Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 38th largest by enrollment, is one of 15 that started in 2019, is one of 11 in phase 3, and was the 39th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

Primary Objective: To evaluate the pharmacokinetics (PK) of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeries.

Secondary Objective: To evaluate the safety of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeries.

Read the detailed description

This is a Phase 3, two-part, multi-center, open-label study designed to evaluate the PK and safety profile of EXPAREL in pediatric subjects aged 6 to less than 17 years when administered intraoperatively at the end of surgery via local infiltration. 90 pediatric subjects undergoing spine and/or cardiac surgeries are planned for enrollment.

Part 1 is a multicenter, randomized, open-label study in subjects aged 6 to less than 17 years undergoing spine or cardiac surgeries. There will be 2 treatment groups: Group 1 will include subjects aged 12 to less than 17 years, while Group 2 will include subjects aged 6 to less than 12 years

Part 2 is a multicenter, randomized, open-label, safety study in subjects aged 6 to less than 17 years undergoing spine or cardiac surgeries. There will be 2 treatment groups: Group 1 will include subjects aged 12 to less than 17 years, while Group 2 will include subjects aged 6 to less than 12 years.

Subjects will be screened within 30 days prior to study drug administration. During the screening visit, subjects will be assessed for past or present neurologic, cardiac, and general medical conditions that, in the opinion of the investigator, would preclude them from study participation.

Subjects will undergo their pre-planned spinal or cardiac surgeries per the institution's standard of care. On Day 1, eligible subjects will receive the study drug intraoperatively at the end of surgery via local infiltration into the surgical site. Dosing of EXPAREL will be based on body weight, with a starting dose of 4 mg/kg (maximum 266 mg).

There is no required length of stay in the hospital; subjects may be discharged based on the medical judgment of the treating physician.

A follow-up phone call will be scheduled for all subjects on Day 7. A final follow-up visit will be made on Day 30 to all subjects who would have received the study drug.

03

Conditions studied

  • Postoperative Pain Management

Browse trials for

Keywords

  • Pediatric
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects whose parent(s) or guardian(s) has/have signed and dated the ICF for the subject to participate in the study, and subjects who have provided written assent to participate in the study (if capable).
  2. (ASA) Class 1-3.
  3. Male or female subjects 6 to less than 17 years of age on the day of surgery.
  4. (BMI) at screening within the 5th to 95th percentile for age and sex (see Appendix 5).
  5. A negative pregnancy test for female subjects of must be available prior to the start of surgery. The pregnancy test must be conducted in the preoperative holding area according to the study site's standard of care.
  6. Subjects and their parent(s)/guardian(s) must be able to speak, read, and understand the language of the ICF and any instruments used for collecting subject-reported outcomes to enable accurate and appropriate responses to study assessments, and provide /assent.
  7. Subjects must be able to adhere to the study visit schedule and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. Currently pregnant, breastfeeding, or planning to become pregnant during the study or within 1 month after study drug administration.
  2. History of or idiosyncratic reactions to amide-type local anesthetics or to opioid medication.
  3. to bupivacaine HCl or other amide-type local anesthetics or to opioid medication.
  4. Administration of EXPAREL or bupivacaine HCl within 30 days prior to study drug administration.
  5. Subjects with coagulopathies or immunodeficiency disorders.
  6. History of, suspected, or known addiction to or abuse of drugs or alcohol within the past 2 years.
  7. medical or psychiatric disease that, in the opinion of the investigator, indicates an increased vulnerability to study drugs and/or procedures.
  8. Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.

    In addition, the subject will be ineligible to receive study drug if he or she meets the following criterion during surgery:

  9. Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's postsurgical course.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Group 1: 12 to less than 17 years, undergoing spine surgery, EXPAREL

    Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.

    Drug: Exparel

  • Active comparator
    Group 1: 12 to less than 17 years, undergoing spine surgery, bupivacine

    Single dose of bupivacaine hydrochloride (HCl) 2 mg/kg (not to exceed a maximum total dose of 175 mg) via local infiltration at the end of spine surgery.

    Drug: 0.5% Bupivacaine HCl

  • Experimental
    Group 2: 6 to less than 12 years, undergoing spine surgery, EXPAREL

    Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.

    Drug: Exparel

  • Experimental
    Group 2: 6 to less than 12 years, undergoing cardiac surgery, EXPAREL

    Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of cardiac surgery.

    Drug: Exparel

Interventions

  • EXPAREL 4mg/kg (maximum 266 mg)

    Also known as: Liposomal bupivacaine

  • Bupivacaine HCl 2mg/kg

    Also known as: Bupivacaine

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Infinity

    Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)

  2. Maximum Plasma Concentration (Cmax)

    Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)

  3. The Apparent Terminal Elimination Half-life (t1/2el)

    Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)

  4. Apparent Clearance (CL/F)

    Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)

  5. Apparent Volume of Distribution (Vd/F)

    Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)

  6. Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Tlast

    Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)

07

Results

Posted Jan 6, 2021

Participant flow

Participants were recruited between 02 April 2019 and 24 September 2019 at 15 sites in the US (both Groups).

Participant flow — Overall Study
MilestoneGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL
Started3130630
Completed3028528
Not completed1212
Withdrew: Lost to follow-up1201
Withdrew: Study drug was not administered0011

Outcome measures

PrimaryArea Under the Plasma Concentration-versus-time Curve (AUC) 0 to Infinity
Time frame:
15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
Reported as:
Mean · ng*h/mL
Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Infinity
ng*h/mLGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL
Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Infinity14246.1 ± 9118.835709.4 ± 3281.7411569.5 ± 7306.0726164.0 ± 28038.35
PrimaryMaximum Plasma Concentration (Cmax)
Time frame:
15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax)
ng/mLGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL
Maximum Plasma Concentration (Cmax)357.3 ± 125.31563.6 ± 320.93319.5 ± 164.76447.1 ± 243.41
PrimaryThe Apparent Terminal Elimination Half-life (t1/2el)
Time frame:
15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
Reported as:
Mean · hours
The Apparent Terminal Elimination Half-life (t1/2el)
hoursGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL
The Apparent Terminal Elimination Half-life (t1/2el)26.8 ± 21.268.4 ± 6.2613.4 ± 4.6024.9 ± 20.58
PrimaryApparent Clearance (CL/F)
Time frame:
15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
Reported as:
Mean · Liters/hour
Apparent Clearance (CL/F)
Liters/hourGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL
Apparent Clearance (CL/F)17.5 ± 7.4720.5 ± 8.2714.5 ± 2.707.4 ± 3.20
PrimaryApparent Volume of Distribution (Vd/F)
Time frame:
15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
Reported as:
Mean · Liters
Apparent Volume of Distribution (Vd/F)
LitersGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL
Apparent Volume of Distribution (Vd/F)546.4 ± 269.42226.8 ± 110.63271.1 ± 43.58216.1 ± 83.77
PrimaryArea Under the Plasma Concentration-versus-time Curve (AUC) 0 to Tlast
Time frame:
15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
Reported as:
Mean · ng*h/mL
Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Tlast
ng*h/mLGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL
Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Tlast9042.5 ± 3762.825232.9 ± 2538.3710249.6 ± 5956.5616776.4 ± 7935.80

Adverse events

Collected over Screening through postsurgical Day 14. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL0/31 (0%)0/31 (0%)19/31 (61.3%)
Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacaine0/30 (0%)0/30 (0%)22/30 (73.3%)
Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL0/5 (0%)0/5 (0%)5/5 (100%)
Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL0/29 (0%)2/29 (6.9%)9/29 (31%)
Most frequent serious events
Most frequent serious events
EventGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacaineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL
DyspneaRespiratory, thoracic and mediastinal disorders0/310/300/51/29
VomitingGastrointestinal disorders0/310/300/51/29
Wound infection fungalInfections and infestations0/310/300/51/29
Most frequent other events
Showing 10 of 23
Most frequent other events
EventGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacaineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL
Hypoesthesia oralGastrointestinal disorders1/313/303/50/29
Vision blurredEye disorders4/313/303/51/29
HypotensionVascular disorders2/317/302/50/29
PruritisSkin and subcutaneous tissue disorders1/312/302/50/29
NauseaGastrointestinal disorders10/316/301/52/29
ConstipationGastrointestinal disorders8/319/301/54/29
VomitingGastrointestinal disorders9/315/301/54/29
Muscle twitchingMusculoskeletal and connective tissue disorders2/318/301/51/29
DiarrheaGastrointestinal disorders2/310/301/50/29
Muscle spasmsMusculoskeletal and connective tissue disorders3/310/301/50/29

Baseline characteristics

Safety population The Safety population consisted of all subjects who underwent the planned surgery and received study treatment, with analysis by actual treatment received.

Age, Continuous
Age, Continuous(years)Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPARELTotal
Mean13.8 ± 1.3313.9 ± 1.3310 ± 1.738.7 ± 1.7712.1 ± 2.81
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPARELTotal
Female282221466
Male3831529
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPARELTotal
Hispanic or Latino1070926
Not Hispanic or Latino192352067
Unknown or Not Reported20002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPARELTotal
American Indian or Alaska Native00000
Asian20002
Native Hawaiian or Other Pacific Islander00011
Black or African American531211
White212642677
More than one race11002
Unknown or Not Reported20002
Region of Enrollment
Region of Enrollment(participants)Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPARELTotal
United States313052995
American Society of Anesthesiologists classification
American Society of Anesthesiologists classification(Participants)Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPARELGroup 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, BupivacineGroup 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPARELGroup 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPARELTotal
ASA 114131028
ASA 216132233
ASA 31422734
08

Study locations

17 sites
  • Loma Linda University
    Loma Linda, California 92354, United States
  • Shriners Hospitals for Children, Northern California
    Sacramento, California 95817, United States
  • Stanford University
    Stanford, California 94305, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Nemours / Alfred I. DuPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • Shriners Hospitals for Children-Chicago
    Chicago, Illinois 60707, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46204, United States
  • University of Minnesota Masonic Children's Hospital
    Minneapolis, Minnesota 55454, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73110, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • McGovern Medical School at UTHealth
    Houston, Texas 77030, United States
  • Southwest Scoliosis Institute
    Plano, Texas 75075, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Tirotta CF, de Armendi AJ, Horn ND, Hammer GB, Szczodry M, Matuszczak M, Wang NQ, Scranton R, Ballock RT. A multicenter study to evaluate the pharmacokinetics and safety of liposomal bupivacaine for postsurgical analgesia in pediatric patients aged 6 to less than 17 years (PLAY). J Clin Anesth. 2021 Dec;75:110503. doi: 10.1016/j.jclinane.2021.110503. Epub 2021 Sep 14. PubMed 34534923 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Aug 2019, 4 months.

Results were first posted in Jan 2021, 1 year 4 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 4 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2018
First posted
Sep 24, 2018
StartActual
Apr 2, 2019
Primary completionActual
Aug 30, 2019
CompletionActual
Sep 24, 2019
Results first posted
Jan 6, 2021
Last update
Jan 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03682302
Responsible party
Sponsor
First posted
Sep 24, 2018
Start date
Apr 2, 2019
Primary completion
Aug 30, 2019
Completion
Sep 24, 2019
Results posted
Jan 6, 2021
Last update
Jan 6, 2021

Study contacts

Igor Grachev, MD, PhD
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion